Oneness Biotech Co., Ltd. (LUX:ONES)

Market Cap	663.91M -17.4%
Revenue (ttm)	3.81M +19.8%
Net Income	-28.02M
EPS	-0.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	8.40
Day's Range	n/a
52-Week Range	7.75 - 12.90
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Oneness Biotech

Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments. The company offers Fespixon which is a treatment of diabetic foot ulcer; and Bonvadis, a wound care medical device. It also develops FB825, which is in Phase II clinical trial for treating atopic dermatitis and allergic asthma; FB704A which is in Phase II clinical trial for the treatment of rhe...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2008
• Employees: 43
• Stock Exchange: Luxembourg Stock Exchange
• Ticker Symbol: ONES

Financial Performance

In 2025, Oneness Biotech's revenue was 129.12 million, an increase of 9.49% compared to the previous year's 117.93 million. Losses were -1.04 billion, -10.33% less than in 2024.

Financial numbers in TWD